SIGMAR1 and cancer: Given this domain structure, detailed pharmacogenetic studies using disease-associated and created mutants of SigmaR1 will be an important approach to understanding its diverse and specific functions as well as identifying the locations of ligand-binding towards the effective clinical utility in cancer treatment.